In vitro activity of rifampicin alone and in combination with imipenem against multidrug-resistant Acinetobacter baumannii harboring the blaOXA-72 resistance gene

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 4, 2014, Pages 260-264

  Majewski, Piotr ^a   Wieczorek, Piotr ^a   Ojdana, Dominika ^a   Sacha, Paweł Tomasz ^a   Wieczorek, Anna ^a   Tryniszewska, Elzbieta Anna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acinetobacter baumannii; Combination treatment; Imipenem; Multidrug resistance; Rifampicin

Indexed keywords

IMIPENEM; RIFAMPICIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; FRACTIONAL INHIBITORY CONCENTRATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII; NONHUMAN; TITRIMETRY; ACINETOBACTER INFECTIONS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; RIFAMPIN;

EID: 84899012848     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.865141     Document Type: Article

References (41)

1. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64: 129-36.
2. Nordmann P, Naas T, Poirel L. G lobal spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 7: 1791-8.
3. Majewski P, Sacha PT, Wieczorek P, Ojdana D, Michalska AD, Tryniszewska E. New Delhi metallo-lactamases-the dawn of post-antibiotic era? Prog Health Sci 2012; 2: 153-60.
4. Jane R, Danziger H. M ultidrug resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38: 1449-59.
5. Zavascki AP, Carvalhaes C G, Picao R C, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010; 8: 71-93.
6. Wieczorek P, Sacha PT, Hauschild T, Zorawski T, Krawczyk M, Tryniszewska E. Multidrug-resistant Acinetobacter baumannii-the role of AdeABC (RND family) effl ux pump in resistance to antibiotics. Folia Histochem Cytobiol 2008; 46: 257-67.
7. Bakour S, Touati A, Sahli F, Ameur A A, Haouchine D, Rolain JM. Antibiotic resistance determinants of multidrugresistant Acinetobacter baumannii clinical isolates in Algeria. Diagn Microbiol Infect Dis 2013; 76: 529-31.
8. Strateva T, Markova B, Marteva-Proevska Y, Ivanova D, Mitov I. Widespread dissemination of multidrug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase and ArmA 16S ribosomal RNA methylase in a Bulgarian university hospital. Braz J Infect Dis 2012; 16: 307-10.
9. Queenan AM, Bush K. C arbapenemases: the versatile betalactamases. Clin Microbiol Rev 2007; 20: 440-58.
10. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, et al. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 2012; 7: e37788.
11. Kempf M, Rolain JM, Diatta G, Azza S, Samb B, Mediannikov O, et al. Carbapenem resistance in Acinetobacter baumannii in Senegal: the paradigm of a common phenomenon in natural reservoirs. PLoS One 2012; 7: e39495.
12. Superti S V, Martins Dde S, Caierao J, Soares Fda S, Prochnow T, Zavascki AP. Indications for carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration. Rev Inst Med Trop Sao Paulo 2009; 51: 111-3.
13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske GC, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard defi nitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
14. Zavascki AP, Li J, Nation RL, Superti SV, Barth AL, Lutz L, et al. Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organism from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug. J Clin Microbiol 2009; 47: 3064-5.
15. Gales AC, Sader HS, Fritsche TR. T igecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008; 60: 421-7.
16. AP, Li J. I ntravenous colistimethate for multidrugresistant Gram-negative bacteria. Lancet Infect Dis 2008; 8: 403-5.
17. Reis AO, Deise Luz AM, Tognim MC, Sader HS, Gales AC. Polymyxin-resistant Acinetobacter spp. isolates: what is next? Emerg Infect Dis 2003; 9: 1025-7.
18. Forrest GN, Tamura K. R ifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23: 14-34.
19. Sanders WE Jr. R ifampin. Ann Intern Med 1 976; 8 5: 8 2-6.
20. Pachon-Ibanez ME, Fernandez-Cuenca F, Docobo-Perez F, Pachon J, Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in experimental pneumonia murine model, using rifampin associated with imipenem or sulbactam. J Antimicrob Chemother 2006; 58: 689-92.
21. The European Committee of Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect 2003; 9: ix-xv.
22. The European Committee of Antimicrobial Susceptibility testing (EUCAST), Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1. EUCAST; 2013.
23. Soussy CJ. R ecommandations. Comité de l' A ntibiogramme de la Soci é t é Fran ç aise de Microbiologie; 2012. Available at: http://www.sfm-microbiologie.org/UserFiles/file/CASFM/CASFM-2012.pdf (accessed 30 June 2013).
24. Yin XL, Hou TW, Xu SB, Ma CQ, Yao ZY, Li W, et al. Detection of drug resistance-associated genes of multidrugresistant Acinetobacter baumannii. Microb Drug Resist 2008; 14: 145-50.
25. Koeleman JG, Sttoof J, Van Der Bijl MW, Vandenborucke-Grauls CM, Savelkoul PH. Identifi cation of epidemic strains of Acinetobacter baumannii by integrase gene PCR. J Clin Microbiol 2001; 39: 8-13.
26. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224-8.
27. Tan YT, Ng LS, Tan E, Huang G. In vitro effects of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 60: 421-3.
28. The European Committee of Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503-8.
29. Corbella X, Montero A, Pujol MI, Dominguez MA, Ayats K, Argerich MJ, et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38: 4086-95.
30. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-fi eld electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-9.
31. Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007; 30: 537-40.
32. Wolff M, Joly-Guilou ML, Farinotti R, Carbon C. In vivo effi cacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999; 43: 1406-11.
33. Montero A, Ariza J, Corbella X, Domenech A, Carbellos C, Ayats J, et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004; 54: 1085-91.
34. Sabbals M, Pujol M, Tubau F, Pena C, Montero A, Dominguez MA, et al. Rifampin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2005; 58: 697-700.
35. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. E ffi cacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 2009; 33: 33-9.
36. Pachon-Ibanez M E, Docobo-Perez F, Lopez-Rojas R, Dominguez-Herrera J, Jimenez-Mejias ME, Garcia-Curiel A, et al. Effi cacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 1165-72.
37. Clock S A, Tabibi S, Alba L, Kubin C J, Whittier S, Saiman L. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2013; 76: 343-6.
38. Rodriguez CH, De Ambrosio, A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, et al. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J Infect Dev Ctries 2010; 29: 164-7.
39. P achon-Ibanez ME, Docobo-Perez F, Jimenez-Mejias ME, Ibanez-Martinez J, Garcia-Curiel A, Pichardo C, et al. Effi-cacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains. Eur J Clin Microbiol Infect Dis 2011; 30: 895-901.
40. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58: 916-29.
41. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57: 349-58.